福泰制药在美国肾脏病学会年会上展示了Ruby-3研究的新阶段1/2数据,继续证明Povetacicept在成人IgA肾病和原发性膜性肾病中的最佳治疗潜力。
福泰制药在美国肾脏病学会年会上展示了Ruby-3研究的新阶段1/2数据,继续证明Povetacicept在成人IgA肾病和原发性膜性肾病中的最佳治疗潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.